Log in to search using one of your social media accounts:

 

TECENTRIQ approved in Japan for the treatment of unresectable, advanced or recurrent NSCLC
(Source: Roche Investor Update)
Source: Roche Investor Update - January 19, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis
Roche announced today that the European Commission (EC) has granted marketing authorisation for OCREVUS ® (ocrelizumab) for patients with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for patients with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory ac tivity. (Source: Roche Investor Update)
Source: Roche Investor Update - January 12, 2018 Category: Pharmaceuticals Source Type: news

Roche commences tender offer for all shares of Ignyta, Inc. for US$ 27.00 per share in cash
Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Ignyta, Inc. at a price of US$ 27.00 per share. (Source: Roche Investor Update)
Source: Roche Investor Update - January 10, 2018 Category: Pharmaceuticals Source Type: news

Invitation to Roche's Full Year Results 2017 Presentation
Roche will publish its Full Year Results for 2017 prior to the opening of the Swiss Stock Exchange on Thursday, 1 February 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - January 8, 2018 Category: Pharmaceuticals Source Type: news

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment
Roche announced today that it has entered into a strategic, long-term partnership with GE Healthcare in order to jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualised treatment options for cancer and critical care patients. (Source: Roche Investor Update)
Source: Roche Investor Update - January 8, 2018 Category: Pharmaceuticals Source Type: news

Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas
Roche announced today the launch of the cobas ® Plasma Separation Card. This new solution is a stable and easy-to-use sample collection device for HIV plasma viral load testing. By providing a small amount of a patient’s blood from a fingertip, this specially designed card simplifies blood collection and sample transportation. (Source: Roche Investor Update)
Source: Roche Investor Update - January 4, 2018 Category: Pharmaceuticals Source Type: news

Roche and Ignyta reach definitive merger agreement
Roche and Ignyta, Inc. today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 1.7 billion on a fully diluted basis. This price represents a premium of 74% to Ignyta ’s closing price on 21 December 2017 and a premium of 71% and 89% to Ignyta’s 30-day and 90-day volume weighted average share price on 21 December 2017, respectively. The merger agreement has been unanimously approved by the boards of Ignyta and Roche. (Source: Roche Investor Update)
Source: Roche Investor Update - December 22, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has approved Perjeta ® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - December 21, 2017 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
Roche today announced that the European Commission (EC) has granted a marketing authorisation for Alecensa ® (alectinib) as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 21, 2017 Category: Pharmaceuticals Source Type: news

Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche today announced the first results from the pivotal phase III MURANO study evaluating Venclexta ™/Venclyxto™ (venetoclax) plus MabThera®/Rituxan® (rituximab) compared to bendamustine plus MabThera®/Rituxan® (BR) for the treatment of people with relapsed or refractory chronic lymphocytic leukaemia (CLL). The results showed that a fixed duration of treatment with Venclexta/Venclyxto plus MabThera/Rituxan significantly reduced the risk of disease progression or death (progression-free survival; PFS, as assessed by investigator) by 83% compared with BR (HR=0.17; 95% CI 0.11-0.25; p (Source: Roche Investor Update)
Source: Roche Investor Update - December 12, 2017 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche ’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer
Roche today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) in people whose disease expressed the PD-L1 (programmed death-ligand 1: Expression ≥1%) protein compared with sunitinib for the fir st-line treatment of people who have advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 11, 2017 Category: Pharmaceuticals Source Type: news

Phase II data showed Roche ’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma
Roche today announced positive results from the randomised phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus MabThera ®/Rituxan® (rituximab) (BR) against BR alone in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. (Source: Roche Investor Update)
Source: Roche Investor Update - December 10, 2017 Category: Pharmaceuticals Source Type: news

Roche ’s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibitors
Roche announced today that new data from the ongoing Hemlibra ® (emicizumab) clinical development programme were presented at the 59th American Society of Hematology (ASH) Annual Meeting. (Source: Roche Investor Update)
Source: Roche Investor Update - December 9, 2017 Category: Pharmaceuticals Source Type: news

Roche ’s Hemlibra every four weeks controlled bleeds in phase III study in haemophilia A
Roche today announced positive interim results from the phase III HAVEN 4 study evaluating Hemlibra ® (emicizumab) prophylaxis dosed once every four weeks in adults and adolescents (12 years of age or older) with haemophilia A with and without inhibitors to factor VIII. (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2017 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer
Roche today announced results from the positive, pivotal Phase III IMpower150 study of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (carboplatin and paclitaxel) in people with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2017 Category: Pharmaceuticals Source Type: news

FDA grants Roche ’s Avastin full approval for most aggressive form of brain cancer
Roche announced today that the U.S. Food and Drug Administration (FDA) has granted full approval for Avastin ® (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease). (Source: Roche Investor Update)
Source: Roche Investor Update - December 6, 2017 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche ’s live audio webcast and conference call post ASH 2017
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Wednesday, 13 December 2017, following the American Society of Hematology Annual Meeting (ASH) in Atlanta (9 – 12 December 2017). (Source: Roche Investor Update)
Source: Roche Investor Update - December 6, 2017 Category: Pharmaceuticals Source Type: news

TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) FDA partial clinical hold lifted
Roche today announced that following close consultation and agreement on study modifications with the U.S. Food and Drug Administration (FDA), the partial clinical holds placed on the Phase Ib and Phase Ib/II studies evaluating TECENTRIQ in combination with an immunomodulatory medicine (IMiD) in relapsed/refractory multiple myeloma and relapsed/refractory follicular lymphoma have been lifted. (Source: Roche Investor Update)
Source: Roche Investor Update - December 5, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Foundation Medicine ’s FoundationOne CDx, the first pan-tumour comprehensive genomic profiling assay incorporating a broad range of companion diagnostics
Roche announced today that the US Food and Drug Administration (FDA) has approved FoundationOne CDx ™, Foundation Medicine’s comprehensive companion diagnostic assay for personalised oncology care. (Source: Roche Investor Update)
Source: Roche Investor Update - December 4, 2017 Category: Pharmaceuticals Source Type: news

Invitation to Roche ’s live audio webcast and conference call from ESMO IO 2017
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 7 December 2017, following the ESMO Immuno Oncology Congress (7 – 10 December 2017) in Geneva. (Source: Roche Investor Update)
Source: Roche Investor Update - November 28, 2017 Category: Pharmaceuticals Source Type: news

Roche ’s Hemlibra significantly reduced bleeds in phase III study in haemophilia A
Roche today announced positive results from the phase III HAVEN 3 study evaluating Hemlibra ® (emicizumab) in adults and adolescents (aged 12 years or older) with haemophilia A without inhibitors to factor VIII. The study met its primary endpoint, showing a statistically significant and clinically meaningful reduction in the number of treated bleeds over time in people receiving Hemlibra prophylaxis every week compared to those receiving no prophylaxis. The study also met key secondary endpoints, including a statistically significant and clinically meaningful reduction in the number of treated bleeds over time with Hem...
Source: Roche Investor Update - November 20, 2017 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer
Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) compared to Avastin plus chemotherapy in the first-line treatment of people with advan ced non-squamous non-small cell lung cancer (NSCLC). Initial observations for the co-primary endpoint of overall survival (OS) are encouraging. These d...
Source: Roche Investor Update - November 20, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Gazyva for previously untreated advanced follicular lymphoma
Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva ® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The approval is based on results from the phase III GALLIUM study, which showed superior progression-fre e survival (PFS) for patients who received this Gazyva-based regimen compared with those who received a Rituxan® (rituximab)-based regimen as an initial (first-line) therapy. Follicular lymphoma, the most common slow-growing (indolent) f...
Source: Roche Investor Update - November 17, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Hemlibra (emicizumab-kxwh) for haemophilia A with inhibitors
Roche today announced that the US Food and Drug Administration (FDA) has approved Hemlibra ® (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - November 16, 2017 Category: Pharmaceuticals Source Type: news

Invitation to Roche ’s live audio webcast and conference call post ASH 2017
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Wednesday, 13 December 2017, following the American Society of Hematology Annual Meeting (ASH) in Atlanta (9 – 12 December 2017). (Source: Roche Investor Update)
Source: Roche Investor Update - November 14, 2017 Category: Pharmaceuticals Source Type: news

Roche ’s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of OCREVUS for people with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for people with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity. (Source: Roche Investor Update)
Source: Roche Investor Update - November 10, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation
Roche announced today that the US Food and Drug Administration (FDA) has approved Zelboraf ® (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation. ECD is a rare, serious blood disease characterized by the abnormal multiplication of certain white blood cells called histiocytes, which can invade normal tissues and organs in the body. (Source: Roche Investor Update)
Source: Roche Investor Update - November 7, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Alecensa ® (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Source: Roche Investor Update)
Source: Roche Investor Update - November 7, 2017 Category: Pharmaceuticals Source Type: news

Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
Roche today announced that new data on its approved and investigational medicines for blood diseases will be presented at the 59th American Society of Hematology (ASH) Annual Meeting from 9 – 12 December, in Atlanta. (Source: Roche Investor Update)
Source: Roche Investor Update - November 1, 2017 Category: Pharmaceuticals Source Type: news

New data suggest Roche ’s etrolizumab can provide clinically meaningful improvements in the treatment of two of the most common forms of inflammatory bowel disease
Roche today announced data from two ongoing phase III trials evaluating etrolizumab in patients with inflammatory bowel disease (IBD). (Source: Roche Investor Update)
Source: Roche Investor Update - October 31, 2017 Category: Pharmaceuticals Source Type: news

New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis
Roche announced today that new OCREVUS ® (ocrelizumab) data are being presented at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) – Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting in Paris, France. (Source: Roche Investor Update)
Source: Roche Investor Update - October 27, 2017 Category: Pharmaceuticals Source Type: news

FDA accepts Roche ’s supplemental Biologics License Application for Avastin as a front-line treatment for women with advanced ovarian cancer
Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Avastin ® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin alone, for the front-line treatment of women with advanced ovarian cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - October 26, 2017 Category: Pharmaceuticals Source Type: news

Roche recognised as a global leader for sustainable water management
For the first time, Roche has been identified as a global leader for its actions to manage water more sustainably. CDP, the non-profit global environmental disclosure platform, has awarded Roche a position on this year ’s Water A-List. (Source: Roche Investor Update)
Source: Roche Investor Update - October 24, 2017 Category: Pharmaceuticals Source Type: news

Roche reports strong sales growth in the first nine months of 2017
Group sales rose 5% to CHF 39.4 billion. Sales in the Pharmaceuticals Division increased 5% to CHF 30.6 billion. (Source: Roche Investor Update)
Source: Roche Investor Update - October 19, 2017 Category: Pharmaceuticals Source Type: news

Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS
Roche announced today that new data on OCREVUS ® (ocrelizumab) in people with relapsing and primary progressive forms of multiple sclerosis (MS) will be presented during the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) – Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Me eting in Paris, France, 25 to 28 October. (Source: Roche Investor Update)
Source: Roche Investor Update - October 16, 2017 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC
Roche announced today that the European Union ’s (EU) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Alecensa® (alectinib) as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCL C). (Source: Roche Investor Update)
Source: Roche Investor Update - October 13, 2017 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche's 9 Months Sales 2017 Audio Webcast and Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2017 prior to the opening of the Swiss Stock Exchange on Thursday October 19th, 2017. (Source: Roche Investor Update)
Source: Roche Investor Update - October 12, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus
Roche announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the cobas ® Zika test for use on the cobas 6800/8800 Systems. (Source: Roche Investor Update)
Source: Roche Investor Update - October 6, 2017 Category: Pharmaceuticals Source Type: news

Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams
Roche, today announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-making for cancer patient case reviews in tumor boards, or multi-disciplinary team meetings. (Source: Roche Investor Update)
Source: Roche Investor Update - October 3, 2017 Category: Pharmaceuticals Source Type: news

FDA grants Priority Review for Roche ’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC). The FDA is exp ected to make a decision on approval by 28 January 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - September 29, 2017 Category: Pharmaceuticals Source Type: news

Roche ’s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis
Roche announced today that the Swiss agency for the authorisation and supervision of therapeutic products (Swissmedic) has granted authorisation of OCREVUS ® (ocrelizumab) for the treatment of adult patients with active relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). (Source: Roche Investor Update)
Source: Roche Investor Update - September 28, 2017 Category: Pharmaceuticals Source Type: news

Roche receives EU approval of TECENTRIQ ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Roche today announced that the European Commission (EC) has granted a marketing authorisation for TECENTRIQ (atezolizumab) as a monotherapy for the treatment of people with locally advanced or metastatic non-small cell lung cancer (NSCLC) after they have been previously treated with chemotherapy regardless of PD-L1 status. (Source: Roche Investor Update)
Source: Roche Investor Update - September 22, 2017 Category: Pharmaceuticals Source Type: news

Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma
Roche announced today that the European Commission has approved Gazyvaro ® (obinutuzumab) in combination with chemotherapy, followed by Gazyvaro maintenance in people achieving a response, as a new treatment for previously untreated advanced follicular lymphoma. (Source: Roche Investor Update)
Source: Roche Investor Update - September 22, 2017 Category: Pharmaceuticals Source Type: news

Roche receives European approval for Actemra /RoActemra in giant cell arteritis
Roche announced today that the European Commission (EC) has approved Actemra ®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition. Actemra/RoActemra is the first therapy approved for the treatment of GCA in Europe. (Source: Roche Investor Update)
Source: Roche Investor Update - September 22, 2017 Category: Pharmaceuticals Source Type: news

Invitation to Roche's 9 Months Sales 2017 Audio Webcast and Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2017 prior to the opening of the Swiss Stock Exchange on Thursday October 19th, 2017. (Source: Roche Investor Update)
Source: Roche Investor Update - September 21, 2017 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Investor Update)
Source: Roche Investor Update - September 18, 2017 Category: Pharmaceuticals Source Type: news

TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) partial clinical hold reactive statement
Roche: Based on emerging safety data from clinical trials evaluating pembrolizumab in combination with either lenalidomide or pomalidomide in multiple myeloma, the FDA has requested that a Phase Ib and a Phase Ib/II TECENTRIQ study be placed on partial clinical hold. (Source: Roche Investor Update)
Source: Roche Investor Update - September 15, 2017 Category: Pharmaceuticals Source Type: news

Results of a six-month study combining Roche ’s Esbriet with nintedanib in patients with IPF presented at ERS
Roche today announced results of a six month study combining Esbriet (pirfenidone) and nintedanib treatment, showing a similar safety profile for the combination treatment to that expected for each treatment alone. (Source: Roche Investor Update)
Source: Roche Investor Update - September 13, 2017 Category: Pharmaceuticals Source Type: news

Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma
Roche today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf ® (vemurafenib) in the adjuvant (after surgery) treatment of people with completely resected, BRAF V600 mutation-positive melanoma. (Source: Roche Investor Update)
Source: Roche Investor Update - September 11, 2017 Category: Pharmaceuticals Source Type: news

Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration
Roche today announced that the primary endpoint has not been met in Spectri, the first of two phase III studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). (Source: Roche Investor Update)
Source: Roche Investor Update - September 8, 2017 Category: Pharmaceuticals Source Type: news